Bayer buys Perfuse in $2.4B deal for ph. 2 eye disease prospect
Bayer has struck a deal to buy Perfuse Therapeutics for $300 million upfront. The buyout, which includes up to…
Bayer to Acquire Perfuse for Up to $2.45B, Seeing Ophthalmology Opportunity
Laboratory assistant carries out a quality control in a Bayer laboratory. [Bayer] Bayer has agreed to acquire Perfuse…